HIV-1 antibodies from infection and vaccination: Insights for guiding vaccine design

Trends in Microbiology

Volumn 20, Issue 11, 2012, Pages 532-539

  Bonsignori, Mattia ^a   Alam, S Munir ^a   Liao, Hua Xin ^a   Verkoczy, Laurent ^a   Tomaras, Georgia D ^a   Haynes, Barton F ^a   Moody, M Anthony ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Broadly neutralizing antibodies; HIV 1 vaccine; Immunogen design

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE ACTIVATION; CELL LINEAGE; CLINICAL EFFECTIVENESS; CROSS REACTION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOREGULATION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS ENVELOPE; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

AIDS VACCINES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84867902637     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2012.08.011     Document Type: Review

References (86)

1. World Health Organization (2011) Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access, Progress Report 2011, WHO Press.
2. Plotkin S.A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 2010, 17:1055-1065.
3. Kim J.H., et al. HIV vaccines: lessons learned and the way forward. Curr. Opin. HIV AIDS 2010, 5:428-434.
4. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47:401-409.
5. Amanna I.J., et al. Protective immunity following vaccination: how is it defined?. Hum. Vaccin. 2008, 4:316-319.
6. Baker J.P., Katz S.L. Childhood vaccine development: an overview. Pediatr. Res. 2004, 55:347-356.
7. Plotkin S.A. Six revolutions in vaccinology. Pediatr. Infect. Dis. J. 2005, 24:1-9.
8. Karlsson Hedestam G.B., et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 2008, 6:143-155.
9. Burton D.R., et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233-236.
10. Korber B., et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 2001, 58:19-42.
11. Corti D., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 2010, 120:1663-1673.
12. Moody M.A., et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE 2011, 6:e25797.
13. Hindmarsh P., Leis J. Retroviral DNA integration. Microbiol. Mol. Biol. Rev. 1999, 63:836-843.
14. Plotkin S.A., Plotkin S.L. The development of vaccines: how the past led to the future. Nat. Rev. Microbiol. 2011, 9:889-893.
15. Margolis D.M. Eradication therapies for HIV infection: time to begin again. AIDS Res. Hum. Retroviruses 2011, 27:347-353.
16. Arts E.J., Hazuda D.J. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2012, 2:a007161.
17. Cohen M.S., et al. Acute HIV-1 infection. N. Engl. J. Med. 2011, 364:1943-1954.
18. McMichael A.J., et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 2010, 10:11-23.
19. Wu X., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
20. Walker L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
21. Bonsignori M., et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 2011, 85:9998-10009.
22. Moody M.A., et al. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J. Virol. 2012, 86:7496-7507.
23. Haynes B.F., et al. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012, 30:423-433.
24. Verkoczy L., et al. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 2011, 23:383-390.
25. Gray E.S., et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 2011, 85:4828-4840.
26. Liao H-X., et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 2011, 208:2237-2249.
27. Tomaras G.D., et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008, 82:12449-12463.
28. Goonetilleke N., et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 2009, 206:1253-1272.
29. Liu P., et al. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J. Virol. 2011, 85:11196-11207.
30. Richman D.D., et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4144-4149.
31. Wei X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
32. Simek M.D., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 2009, 83:7337-7348.
33. Shen X., et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 2009, 83:3617-3625.
34. Wu X., et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J. Virol. 2012, 86:5844-5856.
35. Hessell A.J., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433.
36. Montefiori D.C., Mascola J.R. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?. Curr. Opin. HIV AIDS 2009, 4:347-351.
37. Mascola J.R. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002, 20:1922-1925.
38. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
39. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 2004, 4:199-210.
40. Pantophlet R., Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 2006, 24:739-769.
41. Calarese D.A., et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:13372-13377.
42. Buchacher A., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 1994, 10:359-369.
43. McInerney T.L., et al. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 1997, 233:313-326.
44. Roben P., et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 1994, 68:4821-4828.
45. Muster T., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67:6642-6647.
46. Conley A.J., et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:3348-3352.
47. Stiegler G., et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001, 17:1757-1765.
48. Zwick M.B., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.
49. Haynes B.F., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
50. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542-554.
51. Guenaga J., et al. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 2011, 6:e16074.
52. Dennison S.M., et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS ONE 2011, 6:e27824.
53. Verkoczy L., et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:181-186.
54. Verkoczy L., et al. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH × VL knockin mice reveals multiple tolerance controls. J. Immunol. 2011, 187:3785-3797.
55. Rerks-Ngarm S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
56. Montefiori D.C., et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 2012, 206:431-441.
57. Haynes B.F., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
58. Bonsignori M., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 2012, 86:11521-11532.
59. Walker L.M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
60. Wrammert J., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
61. Changela A., et al. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J. Virol. 2011, 85:2524-2535.
62. Pancera M., et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 2010, 84:8098-8110.
63. McLellan J.S., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
64. Pejchal R., et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11483-11488.
65. Walker L.M., et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 2010, 6:e1001028.
66. Corti D., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5:e8805.
67. Zhou T., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
68. Falkowska E., et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 2012, 86:4394-4403.
69. Wu X., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
70. Scheid J.F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
71. Scanlan C.N., et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 2002, 76:7306-7321.
72. Shih T-A.Y., et al. Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat. Immunol. 2002, 3:399-406.
73. Dal Porto J.M., et al. Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J. Exp. Med. 2002, 195:1215-1221.
74. Xiao X., et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 2009, 390:404-409.
75. Tomaras G.D., et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 2011, 85:11502-11519.
76. Shih T-A.Y., et al. Role of BCR affinity in T cell dependent antibody responses in vivo. Nat. Immunol. 2002, 3:570-575.
77. Morris L., et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS ONE 2011, 6:e23532.
78. Alam S.M., et al. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J. Virol. 2011, 85:11725-11731.
79. Zhu Z., et al. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J. Virol. 2011, 85:11401-11408.
80. Dosenovic P., et al. BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. J. Immunol. 2012, 188:6018-6026.
81. ® B/E. Vaccine 2012, 30:832-836.
82. Scheid J.F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
83. Bonsignori M., et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 2012, 86:4688-4692.
84. Doria-Rose N.A., et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J. Virol. 2012, 86:3393-3397.
85. Haynes B.F., et al. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol. Med. 2011, 17:108-116.
86. Friedman J., et al. Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum. PLoS ONE 2012, 7:e37648.